Experimental Ebola vaccine seems safe in first stage - US researchers

World News
27-11-2014 | 02:43
High views
Share
LBCI
Share
LBCI
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
Experimental Ebola vaccine seems safe in first stage - US researchers
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
2min
Experimental Ebola vaccine seems safe in first stage - US researchers
An experimental Ebola vaccine appears safe and triggered signs of immune protection in the first 20 volunteers to test it, US researchers reported on Wednesday.

The vaccine is designed to spur the immune system's production of anti-Ebola antibodies, and people developed them within four weeks of getting the shots at the National Institutes of Health.

Half of the test group received a higher-dose shot, and those people produced more antibodies, said the study published in the New England Journal of Medicine.

Some people also developed a different set of virus-fighting immune cells, named T cells, the study found. That may be important in fending off Ebola, as prior research found that monkeys protected by the vaccine also had that combination response.

Stimulating both types of immune response is "a promising factor," said Dr. Anthony Fauci, director of NIH's National Institute of Allergy and Infectious Diseases, whose employees led the work.

The researchers reported no serious side effects. But two people who received the higher-dose vaccine briefly spiked fevers - one above 103 degrees - which disappeared within a day.

Earlier this month, Fauci told Congress this first-stage testing was promising enough that the US planned much larger studies in West Africa, starting in Liberia in early January, to try to prove whether the vaccine really works.

"Maybe by the mid to the end of the summer of 2015, hopefully we'll get enough good data to be able to determine if the vaccine works or not," Fauci said.

Scientists are racing to develop ways to prevent or treat the virus that has killed more than 5,600 people in West Africa, most of them in Guinea, Liberia and Sierra Leone.

A different Canadian-made vaccine also has begun small safety studies.


REUTERS

Download now the LBCI mobile app
To see the latest news, the latest daily programs in Lebanon and the world
Google Play
App Store
We use
cookies
We use cookies to make
your experience on this
website better.
Accept
Learn More